Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

10.1186/bcr3484

Saved in:

Bibliographic Details
Main Authors:	Dent, R.A, Lindeman, G.J, Clemons, M, Wildiers, H, Chan, A, McCarthy, N.J, Singer, C.F, Lowe, E.S, Watkins, C.L, Carmichael, J
Other Authors:	DUKE-NUS MEDICAL SCHOOL
Format:	Article
Published:	2020
Subjects:	granulocyte colony stimulating factor olaparib paclitaxel taxane derivative antineoplastic agent nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase phthalazine derivative piperazine derivative adult alopecia anemia aphasia article bilirubin blood level breast metastasis cancer combination chemotherapy cancer growth cancer mortality cause of death clinical article constipation continuous infusion diarrhea drug dose reduction drug efficacy drug safety drug tolerability drug withdrawal fatigue female fever gamma glutamyl transferase blood level herpes zoster human lactate dehydrogenase blood level mastitis monotherapy multicenter study multiple cycle treatment multiple organ failure nausea neutropenia neutrophil count optimal drug dose peripheral neuropathy phase 1 clinical trial progression free survival rash side effect skin disease skin infection treatment duration treatment response triple negative breast cancer vomiting aged cohort analysis drug antagonism metastasis middle aged mortality pathology treatment outcome Adult Aged Antineoplastic Combined Chemotherapy Protocols Cohort Studies Female Humans Middle Aged Neoplasm Metastasis Paclitaxel Phthalazines Piperazines Poly(ADP-ribose) Polymerases Treatment Outcome Triple Negative Breast Neoplasms
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/183198
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-183198
record_format	dspace
spelling	sg-nus-scholar.10635-1831982023-09-20T21:48:17Z Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer Dent, R.A Lindeman, G.J Clemons, M Wildiers, H Chan, A McCarthy, N.J Singer, C.F Lowe, E.S Watkins, C.L Carmichael, J DUKE-NUS MEDICAL SCHOOL granulocyte colony stimulating factor olaparib paclitaxel taxane derivative antineoplastic agent nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase olaparib paclitaxel phthalazine derivative piperazine derivative adult alopecia anemia aphasia article bilirubin blood level breast metastasis cancer combination chemotherapy cancer growth cancer mortality cause of death clinical article constipation continuous infusion diarrhea drug dose reduction drug efficacy drug safety drug tolerability drug withdrawal fatigue female fever gamma glutamyl transferase blood level herpes zoster human lactate dehydrogenase blood level mastitis monotherapy multicenter study multiple cycle treatment multiple organ failure nausea neutropenia neutrophil count optimal drug dose peripheral neuropathy phase 1 clinical trial progression free survival rash side effect skin disease skin infection treatment duration treatment response triple negative breast cancer vomiting aged cohort analysis drug antagonism metastasis middle aged mortality pathology treatment outcome Adult Aged Antineoplastic Combined Chemotherapy Protocols Cohort Studies Female Humans Middle Aged Neoplasm Metastasis Paclitaxel Phthalazines Piperazines Poly(ADP-ribose) Polymerases Treatment Outcome Triple Negative Breast Neoplasms 10.1186/bcr3484 Breast Cancer Research 15 5 R88 2020-11-10T00:30:29Z 2020-11-10T00:30:29Z 2013 Article Dent, R.A, Lindeman, G.J, Clemons, M, Wildiers, H, Chan, A, McCarthy, N.J, Singer, C.F, Lowe, E.S, Watkins, C.L, Carmichael, J (2013). Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Research 15 (5) : R88. ScholarBank@NUS Repository. https://doi.org/10.1186/bcr3484 14655411 https://scholarbank.nus.edu.sg/handle/10635/183198 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Unpaywall 20201031
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	granulocyte colony stimulating factor olaparib paclitaxel taxane derivative antineoplastic agent nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase olaparib paclitaxel phthalazine derivative piperazine derivative adult alopecia anemia aphasia article bilirubin blood level breast metastasis cancer combination chemotherapy cancer growth cancer mortality cause of death clinical article constipation continuous infusion diarrhea drug dose reduction drug efficacy drug safety drug tolerability drug withdrawal fatigue female fever gamma glutamyl transferase blood level herpes zoster human lactate dehydrogenase blood level mastitis monotherapy multicenter study multiple cycle treatment multiple organ failure nausea neutropenia neutrophil count optimal drug dose peripheral neuropathy phase 1 clinical trial progression free survival rash side effect skin disease skin infection treatment duration treatment response triple negative breast cancer vomiting aged cohort analysis drug antagonism metastasis middle aged mortality pathology treatment outcome Adult Aged Antineoplastic Combined Chemotherapy Protocols Cohort Studies Female Humans Middle Aged Neoplasm Metastasis Paclitaxel Phthalazines Piperazines Poly(ADP-ribose) Polymerases Treatment Outcome Triple Negative Breast Neoplasms
spellingShingle	granulocyte colony stimulating factor olaparib paclitaxel taxane derivative antineoplastic agent nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase olaparib paclitaxel phthalazine derivative piperazine derivative adult alopecia anemia aphasia article bilirubin blood level breast metastasis cancer combination chemotherapy cancer growth cancer mortality cause of death clinical article constipation continuous infusion diarrhea drug dose reduction drug efficacy drug safety drug tolerability drug withdrawal fatigue female fever gamma glutamyl transferase blood level herpes zoster human lactate dehydrogenase blood level mastitis monotherapy multicenter study multiple cycle treatment multiple organ failure nausea neutropenia neutrophil count optimal drug dose peripheral neuropathy phase 1 clinical trial progression free survival rash side effect skin disease skin infection treatment duration treatment response triple negative breast cancer vomiting aged cohort analysis drug antagonism metastasis middle aged mortality pathology treatment outcome Adult Aged Antineoplastic Combined Chemotherapy Protocols Cohort Studies Female Humans Middle Aged Neoplasm Metastasis Paclitaxel Phthalazines Piperazines Poly(ADP-ribose) Polymerases Treatment Outcome Triple Negative Breast Neoplasms Dent, R.A Lindeman, G.J Clemons, M Wildiers, H Chan, A McCarthy, N.J Singer, C.F Lowe, E.S Watkins, C.L Carmichael, J Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
description	10.1186/bcr3484
author2	DUKE-NUS MEDICAL SCHOOL
author_facet	DUKE-NUS MEDICAL SCHOOL Dent, R.A Lindeman, G.J Clemons, M Wildiers, H Chan, A McCarthy, N.J Singer, C.F Lowe, E.S Watkins, C.L Carmichael, J
format	Article
author	Dent, R.A Lindeman, G.J Clemons, M Wildiers, H Chan, A McCarthy, N.J Singer, C.F Lowe, E.S Watkins, C.L Carmichael, J
author_sort	Dent, R.A
title	Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
title_short	Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
title_full	Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
title_fullStr	Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
title_full_unstemmed	Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
title_sort	phase i trial of the oral parp inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/183198
_version_	1779152960072187904

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

Similar Items